Benzinga | Apr 12, 2021 08:01AM EDT

Catalyst Biosciences Says Expands Protease Medicines Patent Portfolio Of Complement Factor 3 Degraders

Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 10,954,501 B2 entitled "Nucleic Acid Encoding Modified Membrane Type Serine Protease 1 (MTSP-1) Polypeptides and Methods of Use." This patent expands the Company's portfolio of intellectual property covering its complement programs and protease medicines. The patent protects nucleic acids encoding modified proteases that selectively cleave and degrade complement factor 3 (C3), including the lead candidate CB 2782-PEG, Catalyst's potential best-in-class treatment for dry AMD, currently licensed to Biogen. Further coverage of a broad range of additional uses in diseases mediated by complement activation provides protection until at least 2038.



"Building a strong patent intellectual property estate around our protease medicines and complement programs protects our ability to develop multiple assets and create long-term shareholder value," said Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences. "We intend to continue to expand our IP as we develop our pipeline of protease medicines."